Volume 4, Issue 5
Editorialp. 383–385
How important are willingness to participate studies in encouraging patient enrollment in oncology trials?
Author(s): Anand Shah
Editorialp. 391–393
What is the potential of Rho kinase inhibitors in the treatment of glaucoma?
Author(s): Sarah Van de Velde
News and Viewsp. 395–398
News: Effectiveness of Tamiflu during swine flu pandemic assessed
Research Updatep. 399–405
The Medicines for Children Research Network: building on current success as we move forward
Author(s): Sabah G Attar, Vanessa Poustie & Michael W Beresford
Clinical Trail Perspectivep. 407–413
A note on conditional and unconditional allocation concealment
Author(s): Vance W Berger
Review: Clinical Trail Outcomesp. 415–428
Looking backwards to move forward: a review of randomized lung cancer treatment trials to inform future research
Author(s): Richard J Stephens
Review: Clinical Trail Outcomesp. 429–439
Arformoterol: rationale for use in chronic obstructive pulmonary disease
Author(s): Jordan Terasaki, Shawn PE Nishi, Bill T Ameredes & Gulshan Sharm
Review: Clinical Trail Outcomesp. 441–451
BG-12 (dimethyl fumarate) in the treatment of multiple sclerosis
Author(s): Oscar Fernandez
Review: Clinical Trail Outcomesp. 453–461
Rupatadine for the treatment of allergic rhinitis and urticaria: a look at the clinical data
Author(s): Erminia Ridolo, Marcello Montagni, Filippo Fassio, Ilaria Massaro, Oliviero Rossi, Cristoforo Incorvaia & Giorgio Walter Canonica
Review: Clinical Trail Outcomesp. 463–478
Implications of BRCA1 and BRCA2 status for cancer clinical study outcomes
Author(s): Alan Christie, David Cameron & Charlie Gourley
